CD Capital Natural Resources Fund III Monetization of Filo Mining stake for C$158.3 Million
12.1.2023 20:23:00 EET | Business Wire | Press release
CD Capital Natural Resources Fund III ("CD Capital”) successfully monetizes its equity investment in Filo Mining for a total consideration of C$158.3 million.
Filo Mining is a Canadian exploration and development company focused on advancing its 100% owned Filo del Sol copper-gold-silver deposit located in Chile's Region III and adjacent San Juan Province, Argentina. CD took a strategic stake in the company back in 2020 enabling an expansion program of drilling to define deeper sulphide mineralisation. The Filo del Sol project has since been described as a high-sulphidation epithermal copper-gold-silver deposit associated with one or more large porphyry copper-gold systems with overlapping mineralizing events.
This drilling, undertaken over the past couple of years, has delivered some of the most spectacular mineralised intercepts of copper and gold the market has witnessed in decades. Recent drill results, such as the recent announcement of drill hole FSDH071 intersected 1,028.0m at 1.16% CuEq from a depth of 292m, including;172.0m at 2.14% CuEq from 408.0m and 237.5m at 1.49% CuEq from 776.0m, continue this success.
CD Capital was one of the early institutional investors to finance the drilling at Filo and the exploration success has been witnessed not only by the markets but also with Filo Mining attracting investment from BHP, who precipitated a C$100m strategic investment into Filo Mining in May 2022.
CD Capital is proud to have been an early institutional investor, alongside the Lundin Group, to support and finance the exploration and project development. The drilling is proving to be transformative for the company and has positioned it for future growth, confirming CD Capital's vision in supporting the leadership of the Lundin Group and the Filo del Sol project.
Founder & CEO of CD Capital, Carmel Daniele, noted the eventual monetization of the fund’s holding in Filo Mining, was part of the fund's normal course of business and mandate terms, delivering a substantial multiple of invested capital since acquisition. The project has more to deliver and CD looks forward to seeing this project flourish into a leading global copper and gold producer. "CD Capital is proud to have been involved in one of the largest copper discoveries in decades and personally has been one of the highlights of my career to see it come into fruition. It has been a truly spectacular investment for CD Capital Fund III’s investors and we are confident Filo’s journey to more success will continue. We look forward to the opportunity of partnering up on similar world-class projects led by top tier management teams with a strong proven track record, such as the Lundin Group, through the combination of our long-term patient institutional capital and our sector expertise to unlock value from exciting future projects in the pipeline.”
Chairman of the board of Filo Mining, Adam Lundin, commented, "We are appreciative for the support from CD Capital, who again believed in the vision of a Lundin Group entity in its early days. The equity participation alongside the family at the beginning of COVID in 2020 allowed us to continue to advance Filo del Sol into what is turning into truly a world class discovery. I would also like to extend a special thanks to CD Capital’s Founder & CEO, Carmel Daniele, for her continued valuable contributions as a Board member of Filo Mining. It has been an amazing journey and we will continue to unlock more value from this fantastic asset. We look forward to creating further value for CD Capital investors on current and future ventures within the Lundin Group."
About CD Capital Group
Over the past 15 years, London based CD Capital has launched three Private Equity funds, having raised circa US$1 billion in long-term patient capital, predominantly from leading North American institutional investors, including endowments and foundations, family offices and corporate pension funds. CD Capital develops world-class projects globally in precious metals, critical metals for greening the world, as well as fertilisers for global food security. CD Capital has a unique focus on partnering up with repeat management teams that have a strong track record in successfully developing projects in Latin America, such as Brazil, Peru, Argentina, Guatemala as well as Canada, Finland, Greenland and Australia.
CD Capital was founded in 2006 by Ms Daniele, who was one of the first in London to set up a dedicated fund focused on private mining assets and winning the prestigious Mines & Money Fund Manager of the Year award in 2008. Since establishing CD Capital, Ms Daniele has built a world-class investment technical team of industry insiders and has been an active sponsor and employer of women studying mining geology at Imperial College, London, resulting in a successful nomination to the 100 Women in Mining for 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005568/en/
Contact information
Dominic Chapman
Chief Financial Officer
ir@cd-capital.com
+44 (0) 207 389 1450
Carmel Daniele
Founder, CIO & CEO
ir@cd-capital.com
+44 (0) 207 389 1450
www.cd-capital.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
